Company

Shield Therapeutics plc

Headquarters: Gateshead, United Kingdom

Employees: 15

CEO: Mr. Gregory P. Madison

LSE: STX +23.36%

Market Cap

£13.7 Million

GBP as of July 1, 2024

US$17.3 Million

Market Cap History

Shield Therapeutics plc market capitalization over time

Evolution of Shield Therapeutics plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Shield Therapeutics plc

Detailed Description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Shield Therapeutics plc has the following listings and related stock indices.


Stock: LSE: STX wb_incandescent

Stock: FSX: 1JS wb_incandescent

Stock: OTC: SHIEF wb_incandescent

Details

Headquarters:

Northern Design Centre

Baltic Business Quarter

Gateshead, NE8 3DF

United Kingdom

Phone: 44 1915 118 500